Therapie endokrinologischer Erkrankungen

  • G. Brabant

Zusammenfassung

Schilddrüsenhormone sind pleiotrope Wirkstoffe, die durch ihren modulierenden Einfluss auf nahezu alle Steuerungsvorgänge des Körpers von vitaler Bedeutung sind. Sie gehören der Gruppe der Steroidhormone an und üben ihre Wirkung über spezifische nukleare Rezeptoren für Trijodthyronin (T3) aus. Thyroxin (T4), als wichtigstes Sekretionsprodukt der Schilddrüse, enthält 4 Jodatome. Durch ein hochspezifisches System zur Aufnahme von Jod wird das Spurenelement Jod in die Schilddrüse aufgenommen und bei der Synthese von Schilddrüsenhormonen in T4 und T3 eingebaut. Jod beeinflusst allerdings nicht nur die Synthese von Schilddrüsenhormonen, sondern auch deren Sekretion und hat entscheidende Bedeutung für die Regulation des Wachstums der Drüse. In den Zielorganen wird T4 durch Abspaltung eines Jodrestes in das eigentlich bioaktive T3 umgewandelt. Diese Dejodinierung erfolgt mit Hilfe eines gewebsspezifischen Enzyms, einer Dejodase. T3 bildet mit einer Reihe anderer Transkriptionsfaktoren Homo-oder Heterodimere, über die eine Schilddrüsen-spezifische Genregulation gesteuert wird [1–4].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Shepard AR, Eberhardt NL (1993) Molecular mechanism of thyroid hormone action. Clin Lab Med 13: 531–541PubMedGoogle Scholar
  2. 2.
    Schwartz HL, Strait KA, Oppenheimer JH (1993) Molecular mechanism of thyroid hormone action. Clin Lab Med 13: 543–561PubMedGoogle Scholar
  3. 3.
    Braverman LE (1994) Deiodination of thyroid hormones. A thirty year perspectives. Exp Clin Endocrinol 102: 355–363PubMedCrossRefGoogle Scholar
  4. 4.
    Lazar MA (1993) Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14: 184–193PubMedGoogle Scholar
  5. 5.
    Werner and Ingbar’s: The Thyroid (1991) (LE Bravermann and RD Utiger, eds) 6th Edition Lippincott, PhiladelphiaGoogle Scholar
  6. 6.
    Boillon R (1988) Thyroid and antithyroid drugs. In: Side effects of drugs (MNG Dukes, ed). Elsevier Science Publishers BV Annual 13:375380Google Scholar
  7. 7.
    Reinwein D, Benker G, Lazarus JH et al. (1993) A prospective randomized trial of antithyroid drug dose in Graves’ disease, therapy. European Multicenter study group on antithyroid drug treatment, J Clin Endocrinol Metab 76: 1516–1521Google Scholar
  8. 8.
    Boyages SC (1993) Iodine deficiency disorders. J Clin Endocrinol Metab 77: 587–591PubMedCrossRefGoogle Scholar
  9. 9.
    Pharoah PO (1993) Iodine-supplementation trials. Am J Clin Nutr 57 (2 Suppl):276 S-279 SGoogle Scholar
  10. 10.
    Many MC, Denef JF (1992) Iodine and goitre involution. Thyroidology 4: 23–26PubMedGoogle Scholar
  11. 11.
    Ross DS (1992) Thyroid hormone suppressive therapy of sporadic nontoxic goitre. Thyroid 2: 263–269PubMedCrossRefGoogle Scholar
  12. 12.
    Levy M (1993) Propylthiouracil hepatotoxicity. Clin Ped 32: 25–29CrossRefGoogle Scholar
  13. 13.
    Mandel SJ, Brent GA, Larsen PR (1994) Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 4: 129133Google Scholar
  14. 14.
    Meyer-Gessner M, Benker G, Lederbogen S et al. (1994) Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 17: 29–36PubMedGoogle Scholar
  15. 15.
    Roti E, Minelli R, Gardini E et al. (1993) The use and misuse of thyroid hormone. Endocr Rev 14: 401–423PubMedGoogle Scholar
  16. 16.
    Ammon HPT (1991) Antithyreoidal wirksame Stoffe. In: Arzneimittel-neben-und -wechselwirkungen. Wissenschaftliche Verlagsges Stuttgart, 892–902Google Scholar
  17. 17.
    Hashizume K, Ichikawa K, Suzuli S et al. (1991) Administration of thyroxine in trated Graves’ disease. Effects on the level of antibodies to thyroid stimulating hormone receptor antibodies and on the risk of recurrence of hyperthyroidism. N Engl J Med 324: 947–953Google Scholar
  18. 18.
    Burke CW (1985) Adrenocortical insufficiency. Clin Endocrinol Metab 14: 86–95CrossRefGoogle Scholar
  19. 19.
    Nerup JU (1975) Addison’s disease–clinical studies. A report of 108 cases. Acta Endocrinol 76: 549–594Google Scholar
  20. 20.
    Snow K, Jiang NS, Kao PC et al. (1992) Biochemical evaluation of adrenal dysfunction: The laboratory perspective. Mayo Clin Proc 67: 10551067Google Scholar
  21. 21.
    Baniahmad A, Tsai MJ (1993) Mechanisms of transcriptional activation by steroid hormone receptors. J Cell Biochem 51: 151–156PubMedCrossRefGoogle Scholar
  22. 22.
    Schlaghecke R, Kornely E, Santen RT et al. (1992) The effect of longterm glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 326: 226–230PubMedCrossRefGoogle Scholar
  23. 23.
    Guslandi M, Tittobello A (1992) Steroid ulcus: A myth revisited. Br Med J 304: 655–656Google Scholar
  24. 24.
    Smith EP, Boyd J, Frank GR et al. (1994) Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 331: 1056–1060PubMedCrossRefGoogle Scholar
  25. 25.
    Gilliland PF (1983) Endocrine emergencies. Postgrad Med J 74: 215–220Google Scholar
  26. 26.
    Grinspoon SK, Biller BMK (1994) Laboratory assessment of adrenal insufficiency, J Clin Endocrinol Metab 79: 923–931PubMedCrossRefGoogle Scholar
  27. 27.
    Piper JM, Ray WA, Daugherty JR et al. (1991) Corticosteroid use and peptic ulcer disease: role of nonsteroidal antiinflammatory drugs. Ann Int Med 114: 735–740PubMedCrossRefGoogle Scholar
  28. 28.
    Kaiser H, Kley HK (1992) Cortisontherapie, Thieme StuttgartGoogle Scholar
  29. 29.
    Kimberley RP (1992) Glucocorticoid therapy for rheumatic diseases. Curr Opin Rheumatol 4: 325–331CrossRefGoogle Scholar
  30. 30.
    Walsh D, Avashia J (1992) Glucocorticoids in clinical oncology. Clev Clin J Meds 59: 505–515CrossRefGoogle Scholar
  31. 31.
    Werbel SS, Ober KP (1993) Acute adrenal insufficiency. Endocr Metab Clin Nth Am 22: 303–328Google Scholar
  32. 32.
    Kimberly RP (1994) Glucocorticoids. Curr Opin Rheumatol 6: 273–280PubMedCrossRefGoogle Scholar
  33. 33.
    Gower WR Jr (1993) Mechanism of glucocorticoid action. J Florida Med Ass 80: 697–700Google Scholar
  34. 34.
    Boumpas DT, Chrousos GP, Wilder RL et al. (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Int Med 119: 1198–1208PubMedCrossRefGoogle Scholar
  35. 35.
    Danese RD, Aron DC (1994) Cushing’s syndrome and hypertension. Endocrinol Metab Clin Nth Am 23: 299–324Google Scholar
  36. 36.
    Kater CE, Biglieri EG (1994) Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol Metab Clin Nth Am 23: 341–357Google Scholar
  37. 37.
    White PC, Speiser PW (1994) Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin Nth Am 23: 325–339Google Scholar
  38. 38.
    White P (1994) Disorders of aldosterone biosynthesis and action. N Engl J Med 331: 250–258PubMedCrossRefGoogle Scholar
  39. 39.
    Bravo EL (1994) Primary aldosteronism. Issues in diagnosis and management, Endocrinol Metab Clin Nth Am 23: 271–283Google Scholar
  40. 40.
    Reid IR, Veale AG, France JT (1994) Glucocorticoid osteoporosis. J Asthma 31: 7–18PubMedCrossRefGoogle Scholar
  41. 41.
    Tappy L, Randin D, Vollenweider P et al. (1994) Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab 79: 1063–1069PubMedCrossRefGoogle Scholar
  42. 42.
    Parker MG, Arbuckle N, Dauvoiss S et al. (1993) Structure and function of the estrogen receptor. Ann N Y Acad Sci 648: 119–126CrossRefGoogle Scholar
  43. 43.
    Gudermann T, Gromoll J (1993) Molekulare Aspekte des Hypogonadismus. Internist 34: 703–711PubMedGoogle Scholar
  44. 44.
    Behre HM, Nieschlag E (1993) Diagnostik des Hypogonadismus and der Infertilität des Mannes. Internist 34: 719–732PubMedGoogle Scholar
  45. 45.
    Nieschlag E, Behre HM (1993) Therapie des Hypogonadismus und der Interfertilität. Internist 34: 756–766PubMedGoogle Scholar
  46. 46.
    Albert DJ, Walsh ML, Jonik RH (1993) Aggressions in humans: what is its biological foundation. Neurosc Biobehav Rev 17: 405–425CrossRefGoogle Scholar
  47. 47.
    Neumann F (1994) The antiandrogencyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol 102: 1–32PubMedCrossRefGoogle Scholar
  48. 48.
    Khattan J, Spatz A, Culine S et al. (1994) Hepatocellular carcinoma during hormone therapy for prostatic cancer. Am J Clin Oncol 17: 390–392CrossRefGoogle Scholar
  49. 49.
    Labrie F (1993) Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72 (Suppl 12): 3816–3827PubMedCrossRefGoogle Scholar
  50. 50.
    Akaza H, Usami M, Kotake T et al. (1993) A randomized phase 11 trial of flutamide vs. chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan flutamide study group. Jap J Clin Oncol 23: 178–185Google Scholar
  51. 61.
    Cumming DC, Yang JC, Rebar RW et al. (1982) Treatment of hirsutism with spironolactone. JAMA 247: 1295–1302PubMedCrossRefGoogle Scholar
  52. 52.
    Glazer G (1991) Atherogenic effects of anabolic steroids on serum lipid levels. Arch Int Med 151: 1925–1933CrossRefGoogle Scholar
  53. 53.
    Neumann 1, Thierau D, Andrae U et al. (1992) Cyproterone acetat induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in gammaglutamyltranspeptidase-positive cells. Carcinogenesis 13: 373–378PubMedCrossRefGoogle Scholar
  54. 54.
    Leidenberger FA (1992) Klinische Endokrinologie für Frauenärzte, Springer, HeidelbergCrossRefGoogle Scholar
  55. 55.
    Baird DT (1993) Antigestrogens. Br Med Bull 49: 73–87Google Scholar
  56. 56.
    Lupulescu A (1993) Estrogen use and cancer risk: a review. Exp Clin Endocrinol 101: 204–214PubMedCrossRefGoogle Scholar
  57. 57.
    Seed M (1991) Sex hormones, lipoproteins, and cardiovascular risk. Arteriosclerosis 90: 1–7CrossRefGoogle Scholar
  58. 58.
    Seed VM, Crook D (1994) Post-menopausal replacement therapy, coronary heart disease and plasma lipoproteins. Curr Opin Lipidol 5: 48–58PubMedCrossRefGoogle Scholar
  59. 59.
    Kuhl H, Taubert HD (1987) Das Klimakterium. Pathophysiologie - Klinik - Therapie. Thieme, StuttgartGoogle Scholar
  60. 60.
    Taubert HD, Kohl H (1981) Kontrazeption mit Hormonen. Thieme, StuttgartGoogle Scholar
  61. 61.
    Lufkin EG, Ory SJ (1994) Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin Proc 69: 131–135PubMedCrossRefGoogle Scholar
  62. 62.
    Wakeling AE (1993) Are breast tumours resistant to tamoxifen also resistant to pure antiöstrogens? J Ster Biochem Mol Biol 47: 107–114CrossRefGoogle Scholar
  63. 63.
    Breckwoldt M (1990) Niedrig-dosierte Kontrazeptiva und Thrombo-Embolie-Risiko. Stellungnahme der Arbeitsgemeinschaft für gynäkologische Endokrinologie. Frauenarzt 31: 329–333Google Scholar
  64. 64.
    Döhring GK (1988) Empfängnisverhütung. 11. Aufl. Thieme, StuttgartGoogle Scholar
  65. 65.
    Ebeling K, Nischan P, Schindler C (1987) Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J Cancer 39: 427–431PubMedCrossRefGoogle Scholar
  66. 66.
    Loprinzi CL, Michalak JC, Quella SK et al. (1994) Megestrol acetate for the prevention of hot flashes. N Engl J Med 331: 347–352PubMedCrossRefGoogle Scholar
  67. 67.
    Lidegaard O (1993) Oral contraception and risk of a cerebral thromoembolic attack: results of a case-control study. Br Med J 306: 956–961Google Scholar
  68. 68.
    Felson DT, Zhang MPH, Hannan MT et al. (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329: 1141–1146PubMedCrossRefGoogle Scholar
  69. 69.
    Ringe JD, Meiss F (1993) Vermeidung früh-postmenopausaler Knochensubstanzverluste durch transdermale Östrogensubstitution. Dtsch Med Wschr 118: 769–774PubMedCrossRefGoogle Scholar
  70. 70.
    Filicori M, Flamigni C, Dellai P et al. (1994) Treatment of anovulation with pulsatile gonadotropin-releasing hormone: Prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 79: 1215–1220PubMedCrossRefGoogle Scholar
  71. 71.
    Conn PM, Crowley WF (1994) Gonadotropin-releasing hormone and its analogs. Ann Rev Med 45: 391–405PubMedCrossRefGoogle Scholar
  72. 72.
    Schneider HPG, Lauritzen C, Nieschlag E (1988) Grundlagen und Klinik der menschlichen Fortpflanzung. de Gruyter, BerlinGoogle Scholar
  73. 73.
    Riedel M, Brabant G, Rieger K et al. (1994) Growth hormone therapy in adults: rationales, results, and perspectives. Exp Clin Endocrinol 102: 269–354CrossRefGoogle Scholar
  74. 74.
    Flogstad AK, Halse J, Grass P et al. (1994) Comparison of octreotide bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 79: 461–469PubMedCrossRefGoogle Scholar
  75. 75.
    Black PM, Zervas NT, Ridgway EC et al. (1984) Secretory tumors of the pituitary gland. Progress in Endocrine Research and Therapy. Raven Press, New YorkGoogle Scholar
  76. 76.
    Ho KY, Weissberger AJ, Marbach P et al. (1990) Therapeutic efficacy of the somatostatin analogue SMS 201–995 (octreotide) in acromegaly: effects of dose and frequency and long-term safety. Ann Intern Med 112: 173–181PubMedCrossRefGoogle Scholar
  77. 77.
    Sambrook P, Birmingham J, Kelly P et al. (1993) Prevention of corticosteroid osteoporosis. N Engl J Med 328: 1745–1752CrossRefGoogle Scholar
  78. 78.
    Blumsohn A, Herrington K, Hannon RA et al. (1994) The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79: 730–735PubMedCrossRefGoogle Scholar
  79. 79.
    Reid IR, Veale AG, France JT (1994) Glucocorticoid osteoporosis. J Asthma 31: 7–18PubMedCrossRefGoogle Scholar
  80. 80.
    Scharla SH, Ziegler R (1994) Bedeutung des Vitamin D und seiner Metabolite in der Pathogenese und Therapie der Osteoporose. Dtsch Med Wschr 119: 847–851PubMedCrossRefGoogle Scholar
  81. 81.
    Avioli LV (1993) Hormonal alterations and osteoporotic syndomes. J Bone Mineral Res 8 (Suppl. 2): 511–514Google Scholar
  82. 82.
    Prince RL (1994) Counterpoint: Estrogen effects on calcitropic hormones and calcium homeostasis. Endocr Rev 15: 301–309PubMedGoogle Scholar
  83. 83.
    Brancacio D, Gallieni M (1994) Recent advances in intravenous calci-triol treatment. Curr Op Nephr Hyperten 3: 411–416CrossRefGoogle Scholar
  84. 84.
    Seymour DG, Stone M (1994) Prospects for treating osteoporosis in older people. Roy Soc Med 87 (Suppl. 23) 26–30Google Scholar
  85. 85.
    Patel S Lyons AR, Hosking DJ (1993) Drugs used in the treatment of metabolic bone disease, Clinical pharmacology and therapeutic use. Drugs 45: 594–617Google Scholar
  86. 86.
    Register JY (1993) Calcitonin for prevention and treatment of osteoporosis. Am J Med 95:44 S-47 SGoogle Scholar
  87. 87.
    Plosker GL, Goa KL (1994) Clodronat. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47: 945–982Google Scholar
  88. 88.
    Bilezikian JP (1993) Clinical review 51: Management of hypercalcemia. J Clin Endocrinol Metab 77: 1445–1449PubMedCrossRefGoogle Scholar
  89. 89.
    Rodan GA, Balena R (1993) Bisphosphonates in the treatment of metabolic bone diseases. Ann Med 25: 373–378PubMedCrossRefGoogle Scholar
  90. 90.
    Nussbaum SR (1993) Pathophysiology and management of severe hypercalcemia. Endocrinol Metab Nth Am 22: 343–362Google Scholar
  91. 91.
    Federman DD (1994) Life without estrogens. N Eng J Med 331: 10881089Google Scholar
  92. 92.
    Oertel H, Strasburger CJ, Kann P, Quabbe HJ (1998) Empfehlungen zur Indikation der Wachstumshormon-Substitution im Erwachsenenalter Dtsch Med Wschr 123: 883–886Google Scholar
  93. 93.
    Mann K (1997) Diagnose und Therapie von Schilddrüsenerkrankungen. Empfehlungen zur Qualitätssicherung Internist 38: 177–185Google Scholar
  94. 94.
    Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, Gennari C (1997) Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 61: 382–385PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • G. Brabant

There are no affiliations available

Personalised recommendations